

# IMAGIN

## MEDICAL


### Investor Presentation

First Quarter 2019

## Game Changing

## Cancer Care


CSE: IME | OTCQB: IMEXF | Frankfurt & Stuttgart Symbol: DPD2



# Forward-Looking Statements

These materials may contain forward-looking statements relating to the business of Imagin Medical (the “Company” or “Imagin”) including with respect to the progress, timing and completion of the Company’s research, development, and clinical trials for product candidates, the Company’s ability to manufacture, market, commercialize, partner and achieve market acceptance for product candidates, its ability to protect its intellectual property and operate its business without infringing on the intellectual property rights of others, the Company’s estimates for future performance and its estimates regarding anticipated operating losses, future revenues, capital requirements, and its needs for additional financing, and any M&A timelines. Even if the Company’s actual results or development are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of the Company’s results or developments in the future. In some cases, you can identify forward-looking statements by words such as “could”, “should”, “may”, “expect”, “anticipates”, “believes”, “intends”, “estimates”, or similar words. These forward-looking statements are based largely on the Company’s current expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements express or implied by these forward-looking statements. In particular, the Company’s expectations could be affected by, among other things, uncertainties involved in the development and manufacture of medical devices, unexpected results, unexpected regulatory actions or delays, competition in general, the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will, in fact, be realized, and no representation or warranty is given as to the completeness or accuracy of the forward-looking statements contain in these materials.

Imagin is providing the information in these materials as of this date, and we disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.



# Investment Highlights

## Surgical Imaging Company



Developing advanced optic and light sensor technology to dramatically improve physicians' ability to visualize cancer during minimally invasive surgery

- First indication – Bladder Cancer - a “hot-button” urology issue looking for innovation
- Completed 10-patient U Rochester Research Study
- World-class Scientific Advisory Board
- Experienced management team that has done it before
- Strong M&A driven market environment; various liquidity options
- Expected newsflow provides multiple potential near- and mid-term value inflection points

# Endoscopic Market

## Definitions

### Minimally Invasive Surgery



### Minimally Invasive Surgery

- Less muscle cut
- Performed using tiny incisions/natural orifices
- Reduced pain, smaller/no scarring, quicker recovery, shorter hospital stay, less expensive


### Endoscopes

- A medical device with attached light “to look inside”
- Different medical specialties use different types of endoscopes
- Cystoscopes, laparoscopes, gastroscopes, bronchoscopes

**Cystoscopy** – is a procedure that allows doctors to examine the lining of the bladder and the tube that carries urine out of the body

# Bladder Cancer

Most Expensive Cancer to Treat



- \$4B bladder cancer surveillance
- > 600,000 living in fear of recurrence
- > 50% recurrence rate in non-muscle
- 81,190 new cases/year; 17,240 deaths\*


Bladder cancer  
is the 6<sup>th</sup> most  
common cancer  
in the U.S.

# Current Standard of Care – White Light

## Significant Unmet Medical Need Remains

Current endoscopes use white light (visible light) that has been the gold standard for decades  
> 90% of the market


### White Light



*Tumor visible above organ wall*

- Highly effective for visualizing cancerous tumors that protrude above the bladder wall

### Limitations of White Light




*Flat tumors not visible*

- Flat tumors may look the same as normal tissue
- Not effective in visualizing the margins (edges) of the tumor

## Emerging Standard of Care – Blue Light

Contrast Agents Are Used With White Light and a Blue Filter, Inducing Fluorescence




### Benefit:

- Blue light excites fluorescence in the tumor, highlighting the cancerous tissue
- Easier to detect flat cancers and visualize margins
- Blue light added to American Urology Association Guidelines


# Competitive Systems

Must “Toggle” Between White & Blue Imaging Modes

White Light Image



Fluorescence with Blue Light




*White light image shows the full landscape of the bladder but does not highlight cancer.*

*Blue light highlights the cancer but not the exact location in the bladder.*

## Barriers to Adoption:


- Surgeon cannot operate using the blue light image
- Surgeon must manually “switch” between two different images
- Needs one hour for contrast agent to be visible in bladder
- High cost





# New Standard of Care – i/Blue Imaging System

## Imagin Makes Cystoscopy With Blue Light Practical



### i/Blue Imaging System Benefits:

- Simultaneous acquisition of differing images
  - No toggling back and forth
  - Displays white and blue images simultaneously on one monitor
  - Shows cancer in context
  - Enables surgeon to better visualize and resect the cancer
- Adapts seamlessly to most types of endoscopes on the market
- Potentially “sees” the cancer more rapidly
- May expand to physician’s office



# On-going Development

## Disruptive Technology: Multiple Markets

- Focused on expansion into multiple endoscopic procedures
- Abdominal surgery, colorectal, and lung
- With appropriate changes i/Blue can accommodate the most commonly used fluorescing contrast agents, such as Indocyanine green (ICG)
- Initial prototype built, animal bile duct evaluation – data presented



**PROCEEDINGS PAPER:**  
Enhanced visualization of the bile duct via parallel white light and indocyanine green fluorescence laparoscopic imaging  
[Stavros G. Demos](#) ; [Shiro Urayama](#)  
[\[+\] Author Affiliations](#)  
*Proc. SPIE* 8940, Optical Biopsy XII, 89400R (March 17, 2014);  
doi:10.1117/12.2044271

- Combines multiple illumination sources into one system

\*Imagin Medical, Inc. is a development stage company and does not currently have any Medical Device Regulatory Approvals or Clearances to market products in any jurisdiction

# Market Opportunity

Well Protected

## Issued

- U.S. Patent 7,149,567 - *Near-Infrared Spectroscopic Tissue Imaging for Medical Applications*
- U.S. Patent 7,257,437 - *Autofluorescence Detection and Imaging of Bladder Cancer Realized Through a Cystoscope*
- U.S. Patent 8,285,015 - *Simultaneous Acquisition of Differing Image Types*

## Pending

- U.S. Patent Application No. 13/601,918 - *Simultaneous Acquisition of Differing Image Types*
- Additional IP being filed



# Regulatory Overview

## Q-Submission completed


- Study planned to compare i/Blue Imaging System performance to other imaging devices currently on the market
- Device will be used with FDA-approved imaging agents and routes of administration
- Expect 12 month process, but could be longer depending on chosen claims, (e.g., comparable vs. superior)
- Full GMP Compliant Quality Management System (QMS) required
- King & Spalding, LLP, Washington DC, will manage all government regulatory approvals

# Growth Strategy


## Market Entry and Expansion

- Start with bladder cancer surgery and then expand to bladder cancer Fluorescence Imaging biopsy
- Create immediate credibility in the market:
  - Develop physician champions/establish 4 *Centers of Excellence*
- Drive to profitability using 7–10 independent sales reps
- Expand market to include additional medical procedures:


### General




### Gynecology



### Colorectal



### Thoracic



# Experienced Management Team

Strong Track Record of Success

	Experience	Years
<b>Jim Hutchens</b> President and CEO	Origin Partners, Microvasive Endoscopy - Boston Scientific, Microsurge, Choice Therapeutics	30
<b>John Vacha</b> CFO	Intact Medical, Deloitte & Touche	21
<b>Michael Vergano</b> Director of Operations	The Harvest Group, Apple Medical, Ciba Corning Diagnostics, Microsurge, Boston Scientific	30
<b>Jay Eastman</b> Director Development	Optel, Inc., University of Rochester, Laboratory of Laser Energetics, Lucid, Inc.	28
<b>Pam Papineau</b> Director of Regulatory Affairs	Baxter, Boston Scientific, Cogentix (Vision-Sciences)	30
<b>Stephen Ruggles</b> Director of Quality Assurance	Cambridge Endoscopic Devices, Becton Dickinson, C.R. Bard	30



# Strong M&A Environment

If You Can't Beat Them, Buy Them



## PINPOINT

- Introduced Q4, 2007
- White light + ICG fluorescence endoscopic system
- Visualization of blood flow and tissue perfusion during surgery
- Ability to **overlay/combine** white light and fluorescence imaging in real time



## System 1588

- Introduced Q1, 2016
- White light + ICG fluorescence endoscopic system
- Visualization of blood flow and tissue perfusion during surgery
- Surgeons need to **toggle** back and fourth between white light and fluorescence image



June 2017: “Stryker Corp. to acquire Novadaq Technologies for \$701 million”

# Financial Highlights

- Strong cash position
- Up-listed to the OTCQB Venture Market
- Liquidity and share capital  
CSE: IME; OTCQB: IMEXF

## Current Share Structure

Share Class (as of 11/05/2018)	# of Shares
Common Shares	139,020,778
Warrants Outstanding*	22,940,277
Options Outstanding	10,100,000
<b>Fully Diluted Shares Outstanding</b>	<b>172, 061,055</b>

## Insider Ownership

Shares Held by Insiders	8,778,857
Insider Ownership	6.31%

\*April 2020 at \$0.30 = \$6.5 million





# In Summary

## Investment Thesis

### Key Investment Risks Removed, High Investment Return

1

#### Disruptive Imaging Technology

- Significant unmet medical need
- Potential to dramatically reduce bladder cancer recurrence
- Addressing \$750M+ global market

2

#### Mitigated R&D Risk

- Concept is already proven
- Research study completed at University of Rochester Medical Center
- This is an execution play

3

#### Management Team

- Experienced medical device management team
- Strong individual track records of success

4

#### Strong M&A Market

- Most large medical device companies grow by acquisition, not organically
- Company expects to have significant value and multiple liquidity options



# Thank You!

## Contact Information:

**Steve Kilmer**

Investor Relations

(647) 872-4849

[stephen@kilmerlucas.com](mailto:stephen@kilmerlucas.com)